Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/124324
Title: Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort
Author: Fortner, Renée T.
Sarink, Danja
Schock, Helena
Johnson, Theron
Tjønneland, Anne
Olsen, Anja
Overvad, Kim
Affret, Aurélie
His, Mathilde
Boutron-Ruault, Marie-Christine
Boeing, Heiner
Trichopoulou, Antonia
Naska, Androniki
Orfanos, Philippos
Palli, Domenico
Sieri, Sabina
Mattiello, Amalia
Tumino, Rosario
Ricceri, Fulvio
Bueno de Mesquita, H. Bas
Peeters, Petra H. M.
van Gils, Carla H.
Weiderpass, Elisabete
Lund, Eiliv
Quirós, J. Ramón
Agudo, Antonio
Sánchez, María José
Chirlaque, María Dolores
Ardanaz, Eva
Dorronsoro, Miren
Key, Tim
Khaw, Kay-Tee
Rinaldi, Sabina
Dossus, Laure
Gunter, Marc
Merritt, Melissa A.
Riboli, Elio
Kaaks, Rudolf
Keywords: Càncer de mama
Necrosi
Breast cancer
Necrosis
Issue Date: 8-Feb-2017
Publisher: BioMed Central
Abstract: Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study. Methods: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1: 1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: The associations between OPG and ER+ and ER-breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER-breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p(trend) = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER-disease did not differ by menopausal status at blood collection (p(het) = 0.97), and we observed no heterogeneity by HT use at blood collection (p(het) >= 0.43) or age at breast cancer diagnosis (p(het) >= 0.30). Conclusions: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER-breast cancer.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s12916-017-0786-8
It is part of: BMC Medicine, 2017, vol. 15, num. 26
URI: http://hdl.handle.net/2445/124324
Related resource: https://doi.org/10.1186/s12916-017-0786-8
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
FortnerRT.pdf371.91 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons